All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Bayer AG and Cedilla Therapeutics Inc. have entered into an exclusive license agreement to develop and commercialize Cedilla Therapeutics' cyclinE1/cyclin dependent kinase 2 (CDK2) complex inhibitors, which selectively address oncogenic drivers.
